Axogen Inc vs Brookfield Infrastructure Partners LP — how do they compare? Axogen Inc trades at $48.35 (market cap $2.59B), while Brookfield Infrastructure Partners LP trades at $39.38 (market cap $17.46B). The key difference: Brookfield Infrastructure Partners LP is far larger — about 6.7× Axogen Inc's market cap, and Brookfield Infrastructure Partners LP pays a 4.79% dividend while Axogen Inc pays none. Which is the better fit depends on your goals.
| AXGN | BIP | |
|---|---|---|
Market Cap | $2.59B | $17.46B |
Sector | Technology | Industrials |
52-Week High | $48.48 | $42.62 |
52-Week Low | $14.16 | $29.81 |
Enterprise Value | $2.50B | $76.41B |
Dividend Yield | — | 4.79% |
Signals from Pluang's Aura AI — not financial advice
AXGN is trading at $46.43, up 4.69% today, with strong technical momentum and bullish moving average signals. The company reported Q2 2026 revenue growth of 23.1% to $69.7 million and raised full-year guidance to at least $279 million. Despite recent earnings misses, analyst sentiment remains overwhelmingly positive with 84% buy ratings and a $54.33 price target.
The stock presents growth potential driven by expanding nerve care platform adoption and reimbursement improvements, but faces risks from persistent net losses (-$15.7M in 2025) and high valuation multiples (P/S 9.5). Near-term performance hinges on Q3 earnings delivery and continued commercial execution amid competitive pressures.
Brookfield Infrastructure Partners (BIP) trades at $39.04, up 0.26% on the day, with a bullish technical signal and strong analyst support. The stock shows a high P/E ratio of 61.26 but attractive EV/EBITDA of 6.91, while recent earnings misses in Q4 2025 and Q1-Q2 2026 contrast with positive cash flow trends and a 2.6% net income margin. Recent news highlights dividend strength and corporate simplification efforts.
Outlook remains positive with a consensus price target of $44.67, offering ~14% upside, supported by bullish sentiment and infrastructure demand. Risks include earnings volatility, high debt-to-asset ratio of 69.68%, and macroeconomic pressures on profitability. The dividend yield and institutional interest provide stability, but execution on guidance is critical.
Trailing returns across standard periods
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →Brookfield Infrastructure owns and operates high-quality global assets across utilities, transport, midstream, and data sectors. It focuses on generating stable, long-term cash flows from essential infrastructure.
Read more on BIP →